Boltwood Capital Management raised its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,602 shares of the company’s stock after buying an additional 40 shares during the period. Johnson & Johnson accounts for about 1.8% of Boltwood Capital Management’s portfolio, making the stock its 11th largest position. Boltwood Capital Management’s holdings in Johnson & Johnson were worth $2,197,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Horizon Investments LLC increased its position in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock worth $285,000 after buying an additional 8 shares during the last quarter. Landmark Financial Advisors LLC increased its position in Johnson & Johnson by 0.5% in the second quarter. Landmark Financial Advisors LLC now owns 1,979 shares of the company’s stock worth $240,000 after buying an additional 9 shares during the last quarter. Lbmc Investment Advisors LLC increased its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $457,000 after buying an additional 16 shares during the last quarter. Stratford Consulting LLC increased its position in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock worth $388,000 after buying an additional 18 shares during the last quarter. Finally, Taylor Wealth Management Partners increased its position in Johnson & Johnson by 1.3% in the second quarter. Taylor Wealth Management Partners now owns 1,505 shares of the company’s stock worth $183,000 after buying an additional 20 shares during the last quarter. Institutional investors own 65.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 0.94% during mid-day trading on Friday, hitting $114.13. 3,433,340 shares of the company traded hands. The company has a market capitalization of $310.49 billion, a price-to-earnings ratio of 20.03 and a beta of 0.75. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company’s 50-day moving average price is $116.14 and its 200 day moving average price is $118.35.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The company had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. During the same period in the prior year, the company posted $1.49 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a dividend of $0.80 per share. The ex-dividend date is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s dividend payout ratio is presently 56.64%.
JNJ has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective on the stock in a research report on Friday, August 5th. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $124.21 price objective on the stock in a research report on Monday, August 8th. Credit Suisse Group AG reiterated a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a research report on Monday, September 19th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Finally, Jefferies Group cut their price objective on shares of Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 13th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $120.79.
In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the business’s stock in a transaction on Friday, October 21st. The shares were bought at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the transaction, the director now owns 26,520 shares in the company, valued at approximately $3,026,197.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.